13F

Stock

Adial Pharmaceuticals, Inc.

ADIL · held by 23 managers

Reported value

$763.9K

Holders

23

+0 new · −0 exited

Holders’ est. mark

−$25

Price effect on 2 books still in the name

Largest holder

$562K

ARMISTICE CAPITAL, LLC

Notable conviction

Share of each notable manager’s 13F book.

Holder count by quarter

Who holds it

Notable only
InvestorSharesValueEst. markChange
ARMISTICE CAPITAL, LLC2.55M$562K—Held
Citadel219.6K$48.3K—Held
Vanguard156K$34.3K—Held
GEODE CAPITAL MANAGEMENT, LLC155.7K$34.3K—Held
JANE STREET GROUP, LLC121.8K$26.8K—Held
NORTHERN TRUST CORP66K$14.5K—Held
XTX Topco Ltd52.1K$11.5K—Held
Manchester Capital Management LLC48.1K$10.6K—Held
BlackRock, Inc.27.8K$6.11K—Held
StoneX Group Inc.19.5K$4.28K—Held
TWO SIGMA SECURITIES, LLC17.1K$3.76K—Held
SUSQUEHANNA INTERNATIONAL GROUP, LLP12.1K$2.66K—Held
PRIVATE MANAGEMENT GROUP INC10K$2.2K—Held
UBS Group AG9.17K$2.02K—Held
Tower Research Capital LLC (TRC)1.34K$295—Held
SBI Securities Co., Ltd.1.16K$255—Held
BANK OF AMERICA CORP /DE/205$45−$24Cut−$19
WELLS FARGO & COMPANY/MN160$35—Held
HARBOUR INVESTMENTS, INC.99$22—Held
Virtu Financial LLC63.8K$14—Held
Abound Wealth Management27$6—Held
MORGAN STANLEY9$2−$1Cut−$1
CITIGROUP INC1$0—Held

Positions as of Q4 2025. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.